Because the survival capacity of GBM is deeply correlated in the signalling pathways described above, many therapeutic approaches now may aim to rewire the regulatory context of the Bcl-2:beclin-1 complex or to modulate the consequences of its interactions. Here, BCL2 is linked to glioblastoma.